Emerging from the UK, retatrutide, a novel compound , is generating considerable interest within the scientific community regarding its potential for body management . This dual GIP and GLP-1 target agonist seems to provide a significant improvement over current therapies, showing encouraging results in preliminary clinical studies . Researchers be